437 related articles for article (PubMed ID: 3805869)
41. [Role of alveolar macrophages and neutrophils in the defense system against infection of Pseudomonas aeruginosa in the respiratory tract and the effect of derivative of muramyl dipeptide].
Maeda M; Ozaki T; Yasuoka S; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Jan; 28(1):135-42. PubMed ID: 2355674
[TBL] [Abstract][Full Text] [Related]
42. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.
Perez HD; Lipton M; Goldstein IM
J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635
[TBL] [Abstract][Full Text] [Related]
43. In vitro activation of rat neutrophils and alveolar macrophages with IgA and IgG immune complexes. Implications for immune complex-induced lung injury.
Warren JS; Kunkel SL; Johnson KJ; Ward PA
Am J Pathol; 1987 Dec; 129(3):578-88. PubMed ID: 2827492
[TBL] [Abstract][Full Text] [Related]
44. Human monocyte adherence: a primary effect of chemotactic factors on the monocyte to stimulate adherence to human endothelium.
Doherty DE; Haslett C; Tonnesen MG; Henson PM
J Immunol; 1987 Mar; 138(6):1762-71. PubMed ID: 3819394
[TBL] [Abstract][Full Text] [Related]
45. Production of a neutrophil chemotactic factor by endotoxin stimulated alveolar macrophages in vitro.
Snella MC
Br J Exp Pathol; 1986 Dec; 67(6):801-7. PubMed ID: 3542008
[TBL] [Abstract][Full Text] [Related]
46. Fifth component of complement (C5)-derived high-molecular-weight macrophage chemotactic factor in normal guinea pig serum.
Kukita I; Yamamoto T; Kawaguchi T; Kambara T
Inflammation; 1987 Dec; 11(4):459-79. PubMed ID: 3121506
[TBL] [Abstract][Full Text] [Related]
47. Human alveolar macrophage-derived chemotactic factor for neutrophils. Stimuli and partial characterization.
Hunninghake GW; Gadek JE; Fales HM; Crystal RG
J Clin Invest; 1980 Sep; 66(3):473-83. PubMed ID: 6995485
[TBL] [Abstract][Full Text] [Related]
48. Polymorphonuclear leukocyte chemotaxis in systemic lupus erythematosus.
Perez HD; Goldstein IM
J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():53-8. PubMed ID: 3612652
[TBL] [Abstract][Full Text] [Related]
49. Presence of chemotactic peptides other than C5a anaphylatoxin in scales of psoriasis and sterile pustular dermatoses.
Takematsu H; Terui T; Ohkohchi K; Tagami H; Suzuki R; Kumagai K
Acta Derm Venereol; 1986; 66(2):93-7. PubMed ID: 2424251
[TBL] [Abstract][Full Text] [Related]
50. Studies of human C5a as a mediator of inflammation in normal human skin.
Yancey KB; Hammer CH; Harvath L; Renfer L; Frank MM; Lawley TJ
J Clin Invest; 1985 Feb; 75(2):486-95. PubMed ID: 2982914
[TBL] [Abstract][Full Text] [Related]
51. Enhancement of neutrophils function as a result of prior exposure to chemotactic factor.
Van Epps DE; Garcia ML
J Clin Invest; 1980 Aug; 66(2):167-75. PubMed ID: 6249846
[TBL] [Abstract][Full Text] [Related]
52. Cyclocreatine inhibits the production of neutrophil chemotactic factors from isolated hearts.
Elgebaly SA; Allam ME; Rossomando EF; Cordis GA; Forouhar F; Farghaly A; Kreutzer DL
Am J Pathol; 1990 Nov; 137(5):1233-41. PubMed ID: 2240167
[TBL] [Abstract][Full Text] [Related]
53. Complement (C5)-derived chemotactic activity in serum from patients with pancreatitis.
Perez HD; Horn JK; Ong R; Goldstein IM
J Lab Clin Med; 1983 Jan; 101(1):123-9. PubMed ID: 6848611
[TBL] [Abstract][Full Text] [Related]
54. A review on the natural mediators of inflammatory leucotaxis.
Hayashi H
Acta Pathol Jpn; 1982; 32 Suppl 2():271-84. PubMed ID: 6765002
[TBL] [Abstract][Full Text] [Related]
55. A C5a inhibitor in peritoneal fluid.
Matzner Y; Brzezinski A
J Lab Clin Med; 1984 Feb; 103(2):227-35. PubMed ID: 6693795
[TBL] [Abstract][Full Text] [Related]
56. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
[TBL] [Abstract][Full Text] [Related]
57. Contrasting responses to multiple chemotactic stimuli in transendothelial migration: heterologous desensitization in neutrophils and augmentation of migration in eosinophils.
Kitayama J; Carr MW; Roth SJ; Buccola J; Springer TA
J Immunol; 1997 Mar; 158(5):2340-9. PubMed ID: 9036983
[TBL] [Abstract][Full Text] [Related]
58. Study of chemotactic activity developed by neutrophils from rheumatoid arthritis patients.
Bostan M; Constantin MC; Nicolau A; Hirt M; Galatiuc C; Matei I; Braşoveanu LI; Iordăchescu D
Roum Arch Microbiol Immunol; 2002; 61(4):243-58. PubMed ID: 15055258
[TBL] [Abstract][Full Text] [Related]
59. Regulation of alveolar macrophage production of chemoattractants by leukotriene B4 and prostaglandin E2.
Christman JW; Christman BW; Shepherd VL; Rinaldo JE
Am J Respir Cell Mol Biol; 1991 Sep; 5(3):297-304. PubMed ID: 1654953
[TBL] [Abstract][Full Text] [Related]
60. Human leukocyte elastase and cathepsin G are specific inhibitors of C5a-dependent neutrophil enzyme release and chemotaxis.
Tralau T; Meyer-Hoffert U; Schröder JM; Wiedow O
Exp Dermatol; 2004 May; 13(5):316-25. PubMed ID: 15140022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
